Targeting the Mitochondrial Pyruvate Carrier for Neuroprotection
Abstract
:1. Introduction
2. The Mitochondria Pyruvate Carrier
3. Metabolic Insights Arising from the Manipulation of MPC Levels and Activity
4. MPC Inhibition and Neuroprotection
4.1. MPC Inhibition and Protection against Neurotoxic Compounds and Factors
4.2. MPC Inhibition and Protection against Glutamate Excitotoxicity
5. Caveats and Unanswered Questions
6. Is MPC Inhibition a Viable Strategy for Neuroprotection?
7. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Yin, F.; Sancheti, H.; Patil, I.; Cadenas, E. Energy metabolism and inflammation in brain aging and Alzheimer’s disease. Free Radic. Biol. Med. 2016, 100, 108–122. [Google Scholar] [CrossRef] [PubMed]
- Camandola, S.; Mattson, M.P. Brain metabolism in health, aging, and neurodegeneration. EMBO J. 2017, 36, 1474–1492. [Google Scholar] [CrossRef] [PubMed]
- Bose, S.; Ramesh, V.; Locasale, J.W. Acetate metabolism in physiology, cancer, and beyond. Trends Cell Biol. 2019, 29, 695–703. [Google Scholar] [CrossRef] [PubMed]
- Icard, P.; Fournel, L.; Wu, Z.; Alifano, M.; Lincet, H. Interconnection between metabolism and cell cycle in cancer. Trends Biochem. Sci. 2019, 44, 490–501. [Google Scholar] [CrossRef] [PubMed]
- Papadopoli, D.; Boulay, K.; Kazak, L.; Pollak, M.; Mallette, F.; Topisirovic, I.; Hulea, L. mTOR as a central regulator of lifespan and aging. F1000Research 2019, 8. [Google Scholar] [CrossRef]
- Sasaki, Y. Metabolic aspects of neuronal degeneration: From a NAD+ point of view. Neurosci. Res. 2019, 139, 9–20. [Google Scholar] [CrossRef]
- Quansah, E.; Peelaerts, W.; Langston, J.W.; Simon, D.K.; Colca, J.; Brundin, P. Targeting energy metabolism via the mitochondrial pyruvate carrier as a novel approach to attenuate neurodegeneration. Mol. Neurodegener. 2018, 13, 28. [Google Scholar] [CrossRef]
- Gray, L.R.; Tompkins, S.C.; Taylor, E.B. Regulation of pyruvate metabolism and human disease. Cell. Mol. Life Sci. 2014, 71, 2577–2604. [Google Scholar] [CrossRef]
- Palmieri, F.; Monné, M. Discoveries, metabolic roles and diseases of mitochondrial carriers: A review. Biochim. Biophys. Acta 2016, 1863, 2362–2378. [Google Scholar] [CrossRef]
- Bender, T.; Martinou, J.C. The mitochondrial pyruvate carrier in health and disease: To carry or not to carry? Biochim. Biophys. Acta 2016, 1863, 2436–2442. [Google Scholar] [CrossRef]
- Dienel, G.A. The metabolic trinity, glucose-glycogen-lactate, links astrocytes and neurons in brain energetics, signaling, memory, and gene expression. Neurosci. Lett. 2017, 637, 18–25. [Google Scholar] [CrossRef] [PubMed]
- Mergenthaler, P.; Lindauer, U.; Dienel, G.A.; Meisel, A. Sugar for the brain: The role of glucose in physiological and pathological brain function. Trends Neurosci. 2013, 36, 587–597. [Google Scholar] [CrossRef] [PubMed]
- Mason, S. Lactate shuttles in neuroenergetics-homeostasis, allostasis and beyond. Front. Neurosci. 2017, 11, 43. [Google Scholar] [CrossRef] [PubMed]
- Choi, B.Y.; Kim, J.H.; Kim, H.J.; Yoo, J.H.; Song, H.K.; Sohn, M.; Won, S.J.; Suh, S.W. Pyruvate administration reduces recurrent/moderate hypoglycemia-induced cortical neuron death in diabetic rats. PLoS ONE 2013, 8, e81523. [Google Scholar] [CrossRef] [PubMed]
- Izumi, Y.; Zorumski, C.F. Neuroprotective effects of pyruvate following NMDA-mediated excitotoxic insults in hippocampal slices. Neurosci. Lett. 2010, 478, 131–135. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ryou, M.G.; Liu, R.; Ren, M.; Sun, J.; Mallet, R.T.; Yang, S.H. Pyruvate protects the brain against ischemia-reperfusion injury by activating the erythropoietin signaling pathway. Stroke 2012, 43, 1101–1107. [Google Scholar] [CrossRef] [PubMed]
- Moro, N.; Ghavim, S.S.; Harris, N.G.; Hovda, D.A.; Sutton, R.L. Pyruvate treatment attenuates cerebral metabolic depression and neuronal loss after experimental traumatic brain injury. Brain Res. 2016, 1642, 270–277. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Popova, I.; Malkov, A.; Ivanov, A.I.; Samokhina, E.; Buldakova, S.; Gubkina, O.; Osypov, A.; Muhammadiev, R.S.; Zilberter, T.; Molchanov, M.; et al. Metabolic correction by pyruvate halts acquired epilepsy in multiple rodent models. Neurobiol. Dis. 2017, 106, 244–254. [Google Scholar] [CrossRef] [PubMed]
- Tanaka, K.I.; Shimoda, M.; Kawahara, M. Pyruvic acid prevents Cu2+/Zn2+-induced neurotoxicity by suppressing mitochondrial injury. Biochem. Biophys. Res. Commun. 2018, 495, 1335–1341. [Google Scholar] [CrossRef]
- Isopi, E.; Granzotto, A.; Corona, C.; Bomba, M.; Ciavardelli, D.; Curcio, M.; Canzoniero, L.M.T.; Navarra, R.; Lattanzio, R.; Piantelli, M.; et al. Pyruvate prevents the development of age-dependent cognitive deficits in a mouse model of Alzheimer’s disease without reducing amyloid and tau pathology. Neurobiol. Dis. 2015, 81, 214–224. [Google Scholar] [CrossRef]
- Wang, X.; Hu, X.; Yang, Y.; Takata, T.; Sakurai, T. Systemic pyruvate administration markedly reduces neuronal death and cognitive impairment in a rat model of Alzheimer’s disease. Exp. Neurol. 2015, 271, 145–154. [Google Scholar] [CrossRef] [PubMed]
- Rose, S.; Niyazov, D.M.; Rossignol, D.A.; Goldenthal, M.; Kahler, S.G.; Frye, R.E. Clinical and molecular characteristics of mitochondrial dysfunction in Autism Spectrum Disorder. Mol. Diagn. Ther. 2018, 22, 571–593. [Google Scholar] [CrossRef] [PubMed]
- Wu, Y.; Chen, M.; Jiang, J. Mitochondrial dysfunction in neurodegenerative diseases and drug targets via apoptotic signaling. Mitochondrion 2019, 49, 35–45. [Google Scholar] [CrossRef] [PubMed]
- Cowan, K.; Anichtchik, O.; Luo, S. Mitochondrial integrity in neurodegeneration. CNS Neurosci. Ther. 2019, 25, 825–836. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhao, X.Y.; Lu, M.H.; Yuan, D.J.; Xu, D.E.; Yao, P.P.; Ji, W.L.; Chen, H.; Liu, W.L.; Yan, C.X.; Xia, Y.Y.; et al. Mitochondrial dysfunction in neural injury. Front. Neurosci. 2019, 13, 30. [Google Scholar] [CrossRef] [PubMed]
- Ghosh, A.; Tyson, T.; George, S.; Hildebrandt, E.N.; Steiner, J.A.; Madaj, Z.; Schulz, E.; Machiela, E.; McDonald, W.G.; Escobar Galvis, M.L.; et al. Mitochondrial pyruvate carrier regulates autophagy, inflammation, and neurodegeneration in experimental models of Parkinson’s disease. Sci. Transl. Med. 2016, 8, 368ra174. [Google Scholar] [CrossRef] [PubMed]
- Divakaruni, A.S.; Wallace, M.; Buren, C.; Martyniuk, K.; Andreyev, A.Y.; Li, E.; Fields, J.A.; Cordes, T.; Reynolds, I.J.; Bloodgood, B.L.; et al. Inhibition of the mitochondrial pyruvate carrier protects from excitotoxic neuronal death. J. Cell Biol. 2017, 216, 1091–1105. [Google Scholar] [CrossRef]
- McCommis, K.S.; Finck, B.N. Mitochondrial pyruvate transport: A historical perspective and future research directions. Biochem. J. 2015, 466, 443–454. [Google Scholar] [CrossRef]
- Taylor, E.B. Functional properties of the mitochondrial carrier system. Trends Cell Biol. 2017, 27, 633–644. [Google Scholar] [CrossRef]
- Hildyard, J.C.W.; Ammälä, C.; Dukes, I.D.; Thomson, S.A.; Halestrap, A.P. Identification and characterisation of a new class of highly specific and potent inhibitors of the mitochondrial pyruvate carrier. Biochim. Biophys. Acta 2005, 1707, 221–230. [Google Scholar] [CrossRef] [Green Version]
- Thomas, A.P.; Halestrap, A.P. Identification of the protein responsible for pyruvate transport into rat liver and heart mitochondria by specific labelling with [3H] N-phenylmaleimide. Biochem. J. 1981, 196, 471–479. [Google Scholar] [CrossRef] [PubMed]
- Hildyard, J.C.W.; Halestrap, A.P. Identification of the mitochondrial pyruvate carrier in Saccharomyces cerevisiae. Biochem. J. 2003, 374, 607–611. [Google Scholar] [CrossRef] [PubMed]
- Todisco, S.; Agrimi, G.; Castegna, A.; Palmieri, F. Identification of the mitochondrial NAD+ transporter in Saccharomyces cerevisiae. J. Biol. Chem. 2006, 281, 1524–1531. [Google Scholar] [CrossRef] [PubMed]
- Bricker, D.K.; Taylor, E.B.; Schell, J.C.; Orsak, T.; Boutron, A.; Chen, Y.C.; Cox, J.E.; Cardon, C.M.; Van Vranken, J.G.; Dephoure, N.; et al. A mitochondrial pyruvate carrier required for pyruvate uptake in yeast, Drosophila, and humans. Science 2012, 337, 96–100. [Google Scholar] [CrossRef] [PubMed]
- Herzig, S.; Raemy, E.; Montessuit, S.; Veuthey, J.L.; Zamboni, N.; Westermann, B.; Kunji, E.R.S.; Martinou, J.C. Identification and functional expression of the mitochondrial pyruvate carrier. Science 2012, 337, 93–96. [Google Scholar] [CrossRef] [PubMed]
- Schell, J.C.; Rutter, J. The long and winding road to the mitochondrial pyruvate carrier. Cancer Metab. 2013, 1, 6. [Google Scholar] [CrossRef]
- Vanderperre, B.; Cermakova, K.; Escoffier, J.; Kaba, M.; Bender, T.; Nef, S.; Martinou, J.C. MPC1-like Is a placental mammal-specific mitochondrial pyruvate carrier subunit expressed in postmeiotic male germ cells. J. Biol. Chem. 2016, 291, 16448–16461. [Google Scholar] [CrossRef] [PubMed]
- Li, C.L.; Wang, M.; Ma, X.Y.; Zhang, W. NRGA1, a putative mitochondrial pyruvate carrier, mediates ABA regulation of guard cell ion channels and drought stress responses in Arabidopsis. Mol. Plant 2014, 7, 1508–1521. [Google Scholar] [CrossRef] [PubMed]
- Shen, J.L.; Li, C.L.; Wang, M.; He, L.L.; Lin, M.Y.; Chen, D.H.; Zhang, W. Mitochondrial pyruvate carrier 1 mediates abscisic acid-regulated stomatal closure and the drought response by affecting cellular pyruvate content in Arabidopsis thaliana. BMC Plant Biol. 2017, 17, 217. [Google Scholar] [CrossRef]
- Orlandi, I.; Coppola, D.P.; Vai, M. Rewiring yeast acetate metabolism through MPC1 loss of function leads to mitochondrial damage and decreases chronological lifespan. Microb. Cell 2014, 1, 393–405. [Google Scholar] [CrossRef] [Green Version]
- Vanderperre, B.; Herzig, S.; Krznar, P.; Hörl, M.; Ammar, Z.; Montessuit, S.; Pierredon, S.; Zamboni, N.; Martinou, J.C. Embryonic lethality of mitochondrial pyruvate carrier 1 deficient mouse can be rescued by a ketogenic diet. PLoS Genet. 2016, 12, e1006056. [Google Scholar] [CrossRef] [PubMed]
- Vigueira, P.A.; McCommis, K.S.; Schweitzer, G.G.; Remedi, M.S.; Chambers, K.T.; Fu, X.; McDonald, W.G.; Cole, S.L.; Colca, J.R.; Kletzien, R.F.; et al. Mitochondrial pyruvate carrier 2 hypomorphism in mice leads to defects in glucose-stimulated insulin secretion. Cell Rep. 2014, 7, 2042–2053. [Google Scholar] [CrossRef] [PubMed]
- Oonthonpan, L.; Rauckhorst, A.J.; Gray, L.R.; Boutron, A.C.; Taylor, E.B. Two human patient mitochondrial pyruvate carrier mutations reveal distinct molecular mechanisms of dysfunction. JCI Insight 2019, 5. [Google Scholar] [CrossRef] [PubMed]
- Nagampalli, R.S.K.; Quesñay, J.E.N.; Adamoski, D.; Islam, Z.; Birch, J.; Sebinelli, H.G.; Girard, R.M.B.M.; Ascenção, C.F.R.; Fala, A.M.; Pauletti, B.A.; et al. Human mitochondrial pyruvate carrier 2 as an autonomous membrane transporter. Sci. Rep. 2018, 8, 3510. [Google Scholar] [CrossRef] [PubMed]
- Divakaruni, A.S.; Wiley, S.E.; Rogers, G.W.; Andreyev, A.Y.; Petrosyan, S.; Loviscach, M.; Wall, E.A.; Yadava, N.; Heuck, A.P.; Ferrick, D.A.; et al. Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc. Natl. Acad. Sci. USA 2013, 110, 5422–5427. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Tavoulari, S.; Thangaratnarajah, C.; Mavridou, V.; Harbour, M.E.; Martinou, J.C.; Kunji, E.R. The yeast mitochondrial pyruvate carrier is a hetero-dimer in its functional state. EMBO J. 2019, 38, e100785. [Google Scholar] [CrossRef] [PubMed]
- Timón-Gómez, A.; Proft, M.; Pascual-Ahuir, A. Differential regulation of mitochondrial pyruvate carrier genes modulates respiratory capacity and stress tolerance in yeast. PLoS ONE 2013, 8, e79405. [Google Scholar] [CrossRef] [PubMed]
- Bender, T.; Pena, G.; Martinou, J.C. Regulation of mitochondrial pyruvate uptake by alternative pyruvate carrier complexes. EMBO J. 2015, 34, 911–924. [Google Scholar] [CrossRef]
- Patterson, J.N.; Cousteils, K.; Lou, J.W.; Manning Fox, J.E.; MacDonald, P.E.; Joseph, J.W. Mitochondrial metabolism of pyruvate is essential for regulating glucose-stimulated insulin secretion. J. Biol. Chem. 2014, 289, 13335–13346. [Google Scholar] [CrossRef]
- Lehmann, J.M.; Moore, L.B.; Smith-Oliver, T.A.; Wilkison, W.O.; Willson, T.M.; Kliewer, S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J. Biol. Chem. 1995, 270, 12953–12956. [Google Scholar] [CrossRef]
- Hauner, H. The mode of action of thiazolidinediones. Diabetes Metab. Res. Rev. 2002, 18 (Suppl. 2), S10–S15. [Google Scholar] [CrossRef] [PubMed]
- Colca, J.R.; McDonald, W.G.; Cavey, G.S.; Cole, S.L.; Holewa, D.D.; Brightwell-Conrad, A.S.; Wolfe, C.L.; Wheeler, J.S.; Coulter, K.R.; Kilkuskie, P.M.; et al. Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT)-relationship to newly identified mitochondrial pyruvate carrier proteins. PLoS ONE 2013, 8, e61551. [Google Scholar] [CrossRef] [PubMed]
- Colca, J.R.; VanderLugt, J.T.; Adams, W.J.; Shashlo, A.; McDonald, W.G.; Liang, J.; Zhou, R.; Orloff, D.G. Clinical proof-of-concept study with MSDC-0160, a prototype mTOT-modulating insulin sensitizer. Clin. Pharmacol. Ther. 2013, 93, 352–359. [Google Scholar] [CrossRef] [PubMed]
- Chen, Z.; Vigueira, P.A.; Chambers, K.T.; Hall, A.M.; Mitra, M.S.; Qi, N.; McDonald, W.G.; Colca, J.R.; Kletzien, R.F.; Finck, B.N. Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor γ-sparing thiazolidinedione. J. Biol. Chem. 2012, 287, 23537–23548. [Google Scholar] [CrossRef] [PubMed]
- Warburg, O.; Wind, F.; Negelein, E. The metabolism of tumors in the body. J. Gen. Physiol. 1927, 8, 519–530. [Google Scholar] [CrossRef] [PubMed]
- Vander Heiden, M.G.; Cantley, L.C.; Thompson, C.B. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 2009, 324, 1029–1033. [Google Scholar] [CrossRef]
- Iqbal, M.A.; Gupta, V.; Gopinath, P.; Mazurek, S.; Bamezai, R.N.K. Pyruvate kinase M2 and cancer: An updated assessment. FEBS Lett. 2014, 588, 2685–2692. [Google Scholar] [CrossRef] [PubMed]
- Augoff, K.; Hryniewicz-Jankowska, A.; Tabola, R. Lactate dehydrogenase 5: An old friend and a new hope in the war on cancer. Cancer Lett. 2015, 358, 1–7. [Google Scholar] [CrossRef]
- Kim, J.W.; Tchernyshyov, I.; Semenza, G.L.; Dang, C.V. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006, 3, 177–185. [Google Scholar] [CrossRef] [Green Version]
- Schell, J.C.; Olson, K.A.; Jiang, L.; Hawkins, A.J.; Van Vranken, J.G.; Xie, J.; Egnatchik, R.A.; Earl, E.G.; DeBerardinis, R.J.; Rutter, J. A role for the mitochondrial pyruvate carrier as a repressor of the Warburg effect and colon cancer cell growth. Mol. Cell 2014, 56, 400–413. [Google Scholar] [CrossRef]
- Wang, L.; Xu, M.; Qin, J.; Lin, S.C.; Lee, H.J.; Tsai, S.Y.; Tsai, M.J. MPC1, a key gene in cancer metabolism, is regulated by COUPTFII in human prostate cancer. Oncotarget 2016, 7, 14673–14683. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, X.; Ji, Y.; Han, G.; Li, X.; Fan, Z.; Li, Y.; Zhong, Y.; Cao, J.; Zhao, J.; Zhang, M.; et al. MPC1 and MPC2 expressions are associated with favorable clinical outcomes in prostate cancer. BMC Cancer 2016, 16, 894. [Google Scholar] [CrossRef] [PubMed]
- Li, Y.; Li, X.; Kan, Q.; Zhang, M.; Li, X.; Xu, R.; Wang, J.; Yu, D.; Goscinski, M.A.; Wen, J.G.; et al. Mitochondrial pyruvate carrier function is negatively linked to Warburg phenotype in vitro and malignant features in esophageal squamous cell carcinomas. Oncotarget 2017, 8, 1058–1073. [Google Scholar] [CrossRef] [PubMed]
- Schell, J.C.; Wisidagama, D.R.; Bensard, C.; Zhao, H.; Wei, P.; Tanner, J.; Flores, A.; Mohlman, J.; Sorensen, L.K.; Earl, C.S.; et al. Control of intestinal stem cell function and proliferation by mitochondrial pyruvate metabolism. Nat. Cell Biol. 2017, 19, 1027–1036. [Google Scholar] [CrossRef] [PubMed]
- Zou, H.; Chen, Q.; Zhang, A.; Wang, S.; Wu, H.; Yuan, Y.; Wang, S.; Yu, J.; Luo, M.; Wen, X.; et al. MPC1 deficiency accelerates lung adenocarcinoma progression through the STAT3 pathway. Cell Death Dis. 2019, 10, 148. [Google Scholar] [CrossRef]
- Takaoka, Y.; Konno, M.; Koseki, J.; Colvin, H.; Asai, A.; Tamari, K.; Satoh, T.; Mori, M.; Doki, Y.; Ogawa, K.; et al. Mitochondrial pyruvate carrier 1 expression controls cancer epithelial-mesenchymal transition and radioresistance. Cancer Sci. 2019, 110, 1331–1339. [Google Scholar] [CrossRef] [PubMed]
- Bader, D.A.; Hartig, S.M.; Putluri, V.; Foley, C.; Hamilton, M.P.; Smith, E.A.; Saha, P.K.; Panigrahi, A.; Walker, C.; Zong, L.; et al. Mitochondrial pyruvate import is a metabolic vulnerability in androgen receptor-driven prostate cancer. Nat. Metab. 2019, 1, 70–85. [Google Scholar] [CrossRef]
- Tang, X.P.; Chen, Q.; Li, Y.; Wang, Y.; Zou, H.B.; Fu, W.J.; Niu, Q.; Pan, Q.G.; Jiang, P.; Xu, X.S.; et al. Mitochondrial pyruvate carrier 1 functions as a tumor suppressor and predicts the prognosis of human renal cell carcinoma. Lab. Investig. 2019, 99, 191–199. [Google Scholar] [CrossRef]
- Zhong, Y.; Li, X.; Yu, D.; Li, X.; Li, Y.; Long, Y.; Yuan, Y.; Ji, Z.; Zhang, M.; Wen, J.G.; et al. Application of mitochondrial pyruvate carrier blocker UK5099 creates metabolic reprogram and greater stem-like properties in LnCap prostate cancer cells in vitro. Oncotarget 2015, 6, 37758–37769. [Google Scholar] [CrossRef]
- Li, X.; Han, G.; Li, X.; Kan, Q.; Fan, Z.; Li, Y.; Ji, Y.; Zhao, J.; Zhang, M.; Grigalavicius, M.; et al. Mitochondrial pyruvate carrier function determines cell stemness and metabolic reprogramming in cancer cells. Oncotarget 2017, 8, 46363–46380. [Google Scholar] [CrossRef]
- Ohashi, T.; Eguchi, H.; Kawamoto, K.; Konno, M.; Asai, A.; Colvin, H.; Ueda, Y.; Takaoka, H.; Iwagami, Y.; Yamada, D.; et al. Mitochondrial pyruvate carrier modulates the epithelial-mesenchymal transition in cholangiocarcinoma. Oncol. Rep. 2018, 39, 1276–1282. [Google Scholar] [CrossRef] [PubMed]
- Corbet, C.; Bastien, E.; Draoui, N.; Doix, B.; Mignion, L.; Jordan, B.F.; Marchand, A.; Vanherck, J.C.; Chaltin, P.; Schakman, O.; et al. Interruption of lactate uptake by inhibiting mitochondrial pyruvate transport unravels direct antitumor and radiosensitizing effects. Nat. Commun. 2018, 9, 1208. [Google Scholar] [CrossRef] [PubMed]
- Owen, O.E.; Kalhan, S.C.; Hanson, R.W. The key role of anaplerosis and cataplerosis for citric acid cycle function. J. Biol. Chem. 2002, 277, 30409–30412. [Google Scholar] [CrossRef] [PubMed]
- Yang, C.; Sudderth, J.; Dang, T.; Bachoo, R.M.; Bachoo, R.G.; McDonald, J.G.; DeBerardinis, R.J. Glioblastoma cells require glutamate dehydrogenase to survive impairments of glucose metabolism or Akt signaling. Cancer Res. 2009, 69, 7986–7993. [Google Scholar] [CrossRef]
- Yang, C.; Ko, B.; Hensley, C.T.; Jiang, L.; Wasti, A.T.; Kim, J.; Sudderth, J.; Calvaruso, M.A.; Lumata, L.; Mitsche, M.; et al. Glutamine oxidation maintains the TCA cycle and cell survival during impaired mitochondrial pyruvate transport. Mol. Cell 2014, 56, 414–424. [Google Scholar] [CrossRef]
- Vacanti, N.M.; Divakaruni, A.S.; Green, C.R.; Parker, S.J.; Henry, R.R.; Ciaraldi, T.P.; Murphy, A.N.; Metallo, C.M. Regulation of substrate utilization by the mitochondrial pyruvate carrier. Mol. Cell 2014, 56, 425–435. [Google Scholar] [CrossRef] [PubMed]
- Gray, L.R.; Sultana, M.R.; Rauckhorst, A.J.; Oonthonpan, L.; Tompkins, S.C.; Sharma, A.; Fu, X.; Miao, R.; Pewa, A.D.; Brown, K.S.; et al. Hepatic mitochondrial pyruvate carrier 1 is required for efficient regulation of gluconeogenesis and whole-body glucose homeostasis. Cell Metab. 2015, 22, 669–681. [Google Scholar] [CrossRef]
- McCommis, K.S.; Chen, Z.; Fu, X.; McDonald, W.G.; Colca, J.R.; Kletzien, R.F.; Burgess, S.C.; Finck, B.N. Loss of mitochondrial pyruvate carrier 2 in the liver leads to defects in gluconeogenesis and compensation via pyruvate-alanine cycling. Cell Metab. 2015, 22, 682–694. [Google Scholar] [CrossRef]
- Sharma, A.; Oonthonpan, L.; Sheldon, R.D.; Rauckhorst, A.J.; Zhu, Z.; Tompkins, S.C.; Cho, K.; Grzesik, W.J.; Gray, L.R.; Scerbo, D.A.; et al. Impaired skeletal muscle mitochondrial pyruvate uptake rewires glucose metabolism to drive whole-body leanness. eLife 2019, 8, e45873. [Google Scholar] [CrossRef]
- Nordströma, U.; Beauvais, G.; Ghosh, A.; Pulikkaparambil Sasidharan, B.C.; Lundblad, M.; Fuchs, J.; Joshi, R.L.; Lipton, J.W.; Roholt, A.; Medicetty, S.; et al. Progressive nigrostriatal terminal dysfunction and degeneration in the engrailed1 heterozygous mouse model of Parkinson’s disease. Neurobiol. Dis. 2015, 73, 70–82. [Google Scholar] [CrossRef]
- Perluigi, M.; Di Domenico, F.; Butterfield, D.A. mTOR signaling in aging and neurodegeneration: At the crossroad between metabolism dysfunction and impairment of autophagy. Neurobiol. Dis. 2015, 84, 39–49. [Google Scholar] [CrossRef] [PubMed]
- Jahrling, J.B.; Laberge, R.M. Age-related neurodegeneration prevention through mTOR inhibition: Potential mechanisms and remaining questions. Curr. Top. Med. Chem. 2015, 15, 2139–2151. [Google Scholar] [CrossRef] [PubMed]
- Frake, R.A.; Ricketts, T.; Menzies, F.M.; Rubinsztein, D.C. Autophagy and neurodegeneration. J. Clin. Investig. 2015, 125, 65–74. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dello Russo, C.; Lisi, L.; Tringali, G.; Navarra, P. Involvement of mTOR kinase in cytokine-dependent microglial activation and cell proliferation. Biochem. Pharmacol. 2009, 78, 1242–1251. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, D.; Wang, C.; Yao, Y.; Chen, L.; Liu, G.; Zhang, R.; Liu, Q.; Shi, F.D.; Hao, J. mTORC1 pathway disruption ameliorates brain inflammation following stroke via a shift in microglia phenotype from M1 type to M2 type. FASEB J. 2016, 30, 3388–3399. [Google Scholar] [CrossRef] [PubMed]
- Srivastava, I.N.; Shperdheja, J.; Baybis, M.; Ferguson, T.; Crino, P.B. mTOR pathway inhibition prevents neuroinflammation and neuronal death in a mouse model of cerebral palsy. Neurobiol. Dis. 2016, 85, 144–154. [Google Scholar] [CrossRef] [PubMed]
- McKenna, M.C.; Stridh, M.H.; McNair, L.F.; Sonnewald, U.; Waagepetersen, H.S.; Schousboe, A. Glutamate oxidation in astrocytes: Roles of glutamate dehydrogenase and aminotransferases. J. Neurosci. Res. 2016, 94, 1561–1571. [Google Scholar] [CrossRef]
- Hertz, L.; Rothman, D.L. Glutamine-glutamate cycle flux is similar in cultured astrocytes and brain and both glutamate production and oxidation are mainly catalyzed by Aspartate Aminotransferase. Biology 2017, 6, 17. [Google Scholar] [CrossRef]
- Du, J.; Cleghorn, W.M.; Contreras, L.; Lindsay, K.; Rountree, A.M.; Chertov, A.O.; Turner, S.J.; Sahaboglu, A.; Linton, J.; Sadilek, M.; et al. Inhibition of mitochondrial pyruvate transport by zaprinast causes massive accumulation of aspartate at the expense of glutamate in the retina. J. Biol. Chem. 2013, 288, 36129–36140. [Google Scholar] [CrossRef]
- Saxton, R.A.; Sabatini, D.M. mTOR signaling in growth, metabolism, and disease. Cell 2017, 168, 960–976. [Google Scholar] [CrossRef]
- Hardie, D.G. AMPK: Positive and negative regulation, and its role in whole-body energy homeostasis. Curr. Opin. Cell Biol. 2014, 33, 1–7. [Google Scholar] [CrossRef] [PubMed]
- Gwinn, D.M.; Shackelford, D.B.; Egan, D.F.; Mihaylova, M.M.; Mery, A.; Vasquez, D.S.; Turk, B.E.; Shaw, R.J. AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol. Cell 2008, 30, 214–226. [Google Scholar] [CrossRef] [PubMed]
- Inoki, K.; Zhu, T.; Guan, K.L. TSC2 mediates cellular energy response to control cell growth and survival. Cell 2003, 115, 577–590. [Google Scholar] [CrossRef]
- Han, J.M.; Sahin, M. TSC1/TSC2 signaling in the CNS. FEBS Lett. 2011, 585, 973–980. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhou, G.; Myers, R.; Li, Y.; Chen, Y.; Shen, X.; Fenyk-Melody, J.; Wu, M.; Ventre, J.; Doebber, T.; Fujii, N.; et al. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Investig. 2001, 108, 1167–1174. [Google Scholar] [CrossRef] [PubMed]
- Marinangeli, C.; Didier, S.; Vingtdeux, V. AMPK in neurodegenerative diseases: Implications and therapeutic perspectives. Curr. Drug Targets 2016, 17, 890–907. [Google Scholar] [CrossRef] [PubMed]
- Rotermund, C.; Machetanz, G.; Fitzgerald, J.C. The therapeutic potential of Metformin in neurodegenerative diseases. Front. Endocrinol. 2018, 9, 400. [Google Scholar] [CrossRef]
- Gantois, I.; Popic, J.; Khoutorsky, A.; Sonenberg, N. Metformin for treatment of Fragile X Syndrome and other neurological disorders. Annu. Rev. Med. 2019, 70, 167–181. [Google Scholar] [CrossRef]
- Felig, P. The glucose-alanine cycle. Metabolism 1973, 22, 179–207. [Google Scholar] [CrossRef]
- Corbet, C.; Feron, O. Metabolic and mind shifts: From glucose to glutamine and acetate addictions in cancer. Curr. Opin. Clin. Nutr. Metab. Care 2015, 18, 346–353. [Google Scholar] [CrossRef]
- Goubert, E.; Mircheva, Y.; Lasorsa, F.M.; Melon, C.; Profilo, E.; Sutera, J.; Becq, H.; Palmieri, F.; Palmieri, L.; Aniksztejn, L.; et al. Inhibition of the mitochondrial glutamate carrier SLC25A22 in astrocytes leads to intracellular glutamate accumulation. Front. Cell. Neurosci. 2017, 11, 149. [Google Scholar] [CrossRef] [PubMed]
- Mandrekar-Colucci, S.; Karlo, J.C.; Landreth, G.E. Mechanisms underlying the rapid peroxisome proliferator-activated receptor-γ-mediated amyloid clearance and reversal of cognitive deficits in a murine model of Alzheimer’s disease. J. Neurosci. 2012, 32, 10117–10128. [Google Scholar] [CrossRef] [PubMed]
- Pérez, M.J.; Quintanilla, R.A. Therapeutic actions of the Thiazolidinediones in Alzheimer’s disease. PPAR Res. 2015, 2015, 957248. [Google Scholar] [CrossRef] [PubMed]
- Chen, J.; Li, S.; Sun, W.; Li, J. Anti-diabetes drug pioglitazone ameliorates synaptic defects in AD transgenic mice by inhibiting cyclin-dependent kinase5 activity. PLoS ONE 2015, 10, e0123864. [Google Scholar] [CrossRef] [PubMed]
- Galimberti, D.; Scarpini, E. Pioglitazone for the treatment of Alzheimer’s disease. Expert Opin. Investig. Drugs 2017, 26, 97–101. [Google Scholar] [CrossRef] [PubMed]
- Brauer, R.; Bhaskaran, K.; Chaturvedi, N.; Dexter, D.T.; Smeeth, L.; Douglas, I. Glitazone treatment and incidence of Parkinson’s disease among people with diabetes: A retrospective cohort study. PLoS Med. 2015, 12, e1001854. [Google Scholar] [CrossRef] [PubMed]
- NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators. Pioglitazone in early Parkinson’s disease: A phase 2, multicentre, double-blind, randomised trial. Lancet Neurol. 2015, 14, 795–803. [Google Scholar] [CrossRef]
- Connolly, J.G.; Bykov, K.; Gagne, J.J. Thiazolidinediones and Parkinson disease: A cohort study. Am. J. Epidemiol. 2015, 182, 936–944. [Google Scholar] [CrossRef] [PubMed]
- Pinto, M.; Nissanka, N.; Peralta, S.; Brambilla, R.; Diaz, F.; Moraes, C.T. Pioglitazone ameliorates the phenotype of a novel Parkinson’s disease mouse model by reducing neuroinflammation. Mol. Neurodegener. 2016, 11, 25. [Google Scholar] [CrossRef] [PubMed]
- Brakedal, B.; Flønes, I.; Reiter, S.F.; Torkildsen, Ø.; Dölle, C.; Assmus, J.; Haugarvoll, K.; Tzoulis, C. Glitazone use associated with reduced risk of Parkinson’s disease. Mov. Disord. 2017, 32, 1594–1599. [Google Scholar] [CrossRef] [PubMed]
- Schütz, B.; Reimann, J.; Dumitrescu-Ozimek, L.; Kappes-Horn, K.; Landreth, G.E.; Schürmann, B.; Zimmer, A.; Heneka, M.T. The oral antidiabetic pioglitazone protects from neurodegeneration and amyotrophic lateral sclerosis-like symptoms in superoxide dismutase-G93A transgenic mice. J. Neurosci. 2005, 25, 7805–7812. [Google Scholar] [CrossRef] [PubMed]
- Joardar, A.; Menzl, J.; Podolsky, T.C.; Manzo, E.; Estes, P.S.; Ashford, S.; Zarnescu, D.C. PPAR gamma activation is neuroprotective in a Drosophila model of ALS based on TDP-43. Hum. Mol. Genet. 2015, 24, 1741–1754. [Google Scholar] [CrossRef] [PubMed]
- Chiang, M.C.; Chern, Y.; Huang, R.N. PPARgamma rescue of the mitochondrial dysfunction in Huntington’s disease. Neurobiol. Dis. 2012, 45, 322–328. [Google Scholar] [CrossRef] [PubMed]
- Jin, J.; Albertz, J.; Guo, Z.; Peng, Q.; Rudow, G.; Troncoso, J.C.; Ross, C.A.; Duan, W. Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington’s disease. J. Neurochem. 2013, 125, 410–419. [Google Scholar] [CrossRef] [PubMed]
- Chiang, M.C.; Cheng, Y.C.; Nicol, C.J.; Lin, K.H.; Yen, C.H.; Chen, S.J.; Huang, R.N. Rosiglitazone activation of PPARγ-dependent signaling is neuroprotective in mutant huntingtin expressing cells. Exp. Cell Res. 2015, 338, 183–193. [Google Scholar] [CrossRef] [PubMed]
- Leszek, J.; Trypka, E.; Tarasov, V.V.; Ashraf, G.M.; Aliev, G. Type 3 Diabetes Mellitus: A novel implication of Alzheimers disease. Curr. Top. Med. Chem. 2017, 17, 1331–1335. [Google Scholar] [CrossRef] [PubMed]
- Pearson-Leary, J.; McNay, E.C. Novel roles for the insulin-regulated Glucose Transporter-4 in hippocampally dependent memory. J. Neurosci. 2016, 36, 11851–11864. [Google Scholar] [CrossRef] [PubMed]
- Spinelli, M.; Fusco, S.; Grassi, C. Brain insulin resistance and hippocampal plasticity: Mechanisms and biomarkers of cognitive decline. Front. Neurosci. 2019, 13, 788. [Google Scholar] [CrossRef] [PubMed]
- Craig, A.; Parvez, F.; Issberner, J. A systematic literature review of the effect of insulin sensitizers on the cognitive symptoms of Alzheimer’s Disease in transgenic mice. Behav. Brain Res. 2019, 372, 112015. [Google Scholar] [CrossRef]
- Morgan, C.L.; Inzucchi, S.E.; Puelles, J.; Jenkins-Jones, S.; Currie, C.J. Impact of treatment with pioglitazone on stroke outcomes: A real-world database analysis. Diabetes Obes. Metab. 2018, 20, 2140–2147. [Google Scholar] [CrossRef]
- Lee, M.; Saver, J.L.; Liao, H.W.; Lin, C.H.; Ovbiagele, B. Pioglitazone for secondary stroke prevention: A systematic review and meta-analysis. Stroke 2017, 48, 388–393. [Google Scholar] [CrossRef]
- Yaghi, S.; Furie, K.L.; Viscoli, C.M.; Kamel, H.; Gorman, M.; Dearborn, J.; Young, L.H.; Inzucchi, S.E.; Lovejoy, A.M.; Kasner, S.E.; et al. Pioglitazone prevents stroke in patients with a recent transient ischemic attack or ischemic stroke: A planned secondary analysis of the IRIS trial (Insulin Resistance Intervention After Stroke). Circulation 2018, 137, 455–463. [Google Scholar] [CrossRef] [PubMed]
- McGuire, J.L.; Correll, E.A.; Lowery, A.C.; Rhame, K.; Anwar, F.N.; McCullumsmith, R.E.; Ngwenya, L.B. Pioglitazone improves working memory performance when administered in chronic TBI. Neurobiol. Dis. 2019, 132, 104611. [Google Scholar] [CrossRef] [PubMed]
- Phelix, C.; Bourdon, A.; Dugan, J.; Villareal, G.; Perry, G. MSDC-0160 and MSDC-0602 binding with human mitochondrial pyruvate carrier (MPC) 1 and 2 heterodimer: PPARγ activating and sparing TZDs as therapeutics. Int. J. Knowl. Knowl. Bioinform. 2017, 7, 43–67. [Google Scholar] [CrossRef]
- Nancolas, B.; Guo, L.; Zhou, R.; Nath, K.; Nelson, D.S.; Leeper, D.B.; Blair, I.A.; Glickson, J.D.; Halestrap, A.P. The anti-tumour agent lonidamine is a potent inhibitor of the mitochondrial pyruvate carrier and plasma membrane monocarboxylate transporters. Biochem. J. 2016, 473, 929–936. [Google Scholar] [CrossRef] [Green Version]
- Mansi, J.L.; de Graeff, A.; Newell, D.R.; Glaholm, J.; Button, D.; Leach, M.O.; Payne, G.; Smith, I.E. A phase II clinical and pharmacokinetic study of Lonidamine in patients with advanced breast cancer. Br. J. Cancer 1991, 64, 593–597. [Google Scholar] [CrossRef]
- Cheng, G.; Zhang, Q.; Pan, J.; Lee, Y.; Ouari, O.; Hardy, M.; Zielonka, M.; Myers, C.R.; Zielonka, J.; Weh, K.; et al. Targeting lonidamine to mitochondria mitigates lung tumorigenesis and brain metastasis. Nat. Commun. 2019, 10, 2205. [Google Scholar] [CrossRef]
- Di Cosimo, S.; Ferretti, G.; Papaldo, P.; Carlini, P.; Fabi, A.; Cognetti, F. Lonidamine: Efficacy and safety in clinical trials for the treatment of solid tumors. Drugs Today 2003, 39, 157–174. [Google Scholar] [CrossRef]
© 2019 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Tang, B.L. Targeting the Mitochondrial Pyruvate Carrier for Neuroprotection. Brain Sci. 2019, 9, 238. https://doi.org/10.3390/brainsci9090238
Tang BL. Targeting the Mitochondrial Pyruvate Carrier for Neuroprotection. Brain Sciences. 2019; 9(9):238. https://doi.org/10.3390/brainsci9090238
Chicago/Turabian StyleTang, Bor Luen. 2019. "Targeting the Mitochondrial Pyruvate Carrier for Neuroprotection" Brain Sciences 9, no. 9: 238. https://doi.org/10.3390/brainsci9090238